Tiragolumab/Atezolizumab Shows No Benefit in NSCLC ...Middle East

News by : (Medscape) -
A phase 3 study of tiragolumab plus atezolizumab in patients with PD-L1–high NSCLC shows numerical survival improvements but fails to meet statistical endpoints. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Tiragolumab/Atezolizumab Shows No Benefit in NSCLC )

Also on site :

Most Viewed News
جديد الاخبار